Skip to content

Richtech Robotics Inc. RR Indefinite-Lived Research and Development Assets

Indefinite-Lived Research and Development Assets at other companies

HTF
Heartflow, Inc. Common StockHTFL
$15.41M-25.5%
Photronics logo
PhotronicsPLAB
$3.9M+43.5%
KEE
Keel Infrastructure Corp. Common StockKEEL
$2.19M-50.8%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$7.96M-63.4%
Lantheus Holdings logo
Lantheus HoldingsLNTH
$6.19M-79.2%
Frequency Electronics logo
Frequency ElectronicsFEIM
$2.25M+104%

Other financials

Income statement

See full
Revenue$1.1M-8.8%
Gross profit$600.0K-47.1%
Operating income-$11.8M-203%
Net income-$8.4M-137%
EPS (diluted)-$0.040.0%

Balance sheet

See full
Cash & equivalents$271.8M+1,271%
Total debt$719.0K-1.0%
Total equity$339.7M+581%
Total assets$349.4M+579%

Cash flow

See full
Operating cash flow-$1.6M+55.4%
CapEx$71.0K-9.0%
Free cash flow-$1.7M+54.4%

Valuation

See full
Market cap$422.6M+106%
Enterprise value$151.5M-22.4%
P/S85.6×+38.8×

Profitability

See full
Gross margin55.8%-18.1pp
Operating margin-523.9%-1,341pp
Net margin-514.8%-1,899pp
FCF margin-415.7%

Returns & leverage

See full
Return on equity-13%-4.8pp
Debt / equity0.0×
Current ratio35.7×-4.0×

Where this comes from

Reported directly by Richtech Robotics Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment.

The official record: Richtech Robotics Inc.’s 10-K, filed January 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Richtech Robotics Inc.'s indefinite-lived research and development assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Richtech Robotics Inc.'s indefinite-lived research and development assets?
Richtech Robotics Inc. (RR) reported indefinite-lived research and development assets of $889K in Q3 2025.
What does indefinite-lived research and development assets mean?
This represents the value of acquired in-process research and development projects that have not yet reached technological feasibility or commercialization. These assets are not amortized but are subject to periodic impairment testing until the underlying project is completed or abandoned.